Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis

被引:7
|
作者
Jiang, Dandan [1 ]
Ma, Peizhi [1 ]
机构
[1] Peoples Hosp Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Pharm, Zhengzhou, Henan, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
中国国家自然科学基金;
关键词
gastric cancer; HDAC6; EMT; canagliflozin; enzyme inhibition; TARGET;
D O I
10.3389/fonc.2022.1057455
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastric cancer is a common gastrointestinal cancer. Survival outcome for patients with the recurrence or metastasis remains poor due to the lack of effective targeting drugs. The mechanisms of non-histone acetylation modifications are key epigenetic regulations that participate in various biological processes. HDAC6 is mostly located in the cytoplasm to deacetylate non-histone substrates, which has been identified as a critical promoter of many oncogenic pathways in cancers, including gastric cancer. Nevertheless, its inhibitor has not been applied in gastric cancer clinically. In this study, we identified canagliflozin as an active HDAC6-targeted inhibitor from FDA-approved Drug Library by enzymatic assay. The strong affinity of the compounds with HDAC6 was further verified by surface plasmon resonance (SPR) and cellular thermal shift assay (CETSA). In addition, molecular docking showed that canagliflozin could bind to the active pocket of HDAC6 and form interactions with key residues. Further experiments revealed that canagliflozin could effectively inhibit the migration and epithelial-mesenchymal-transition (EMT) of gastric cancer cells in vitro and in vivo. These results reveal a novel finding that canagliflozin has the potential to be an effective agent in inhibiting gastric cancer metastasis.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] Endeavors toward a specific inhibitor for HDAC6
    Kato, Tamaki
    Jose, Binoy
    Okamura, Shinji
    Sumida, Yuko
    Yoshida, Minoru
    Nishino, Norikazu
    PEPTIDE REVOLUTION: GENOMICS, PROTEOMICS & THERAPEUTICS, 2004, : 524 - 525
  • [12] A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer
    Dong, Jing
    Zheng, Nan
    Wang, Xue
    Tang, Chu
    Yan, Ping
    Zhou, Hai-bing
    Huang, Jian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 828 : 67 - 79
  • [13] Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
    Zhou, Maojun
    Zheng, Hao
    Li, Yubin
    Huang, Huichao
    Min, Xiaoli
    Dai, Shuyan
    Zhou, Wenqiang
    Chen, Zhuchu
    Xu, Guangyu
    Chen, Yongheng
    AGING-US, 2021, 13 (05): : 6982 - 6998
  • [14] Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer
    Gajendran, Chandru
    Tantry, Subramanyam Janardhan
    Sadhu, M. Naveen
    Mohammed, Zainuddin
    Dewang, Purushottam
    Hallur, Mahanandeesha
    Nair, Sreekala
    Vaithilingam, Krishnakumar
    Nagayya, Basavaprabhu
    Rajagopal, Sridharan
    Sivanandhan, Dhanalakshmi
    PLOS ONE, 2023, 18 (01):
  • [15] Selective HDAC6 inhibitor decreases lupus in mice
    Ren, Jingjing
    Liao, Xiaofeng
    Vieson, Miranda
    Eden, Kristin
    Chen, Miao
    Scott, Reilly
    Kazmierczak, Jillian
    Luo, Xin M.
    Reilly, Christopher M.
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [16] DISCOVERY OF A NEW HDAC6 INHIBITOR FOR THE TREATMENT OF GLIOBLASTOMA
    Auzmendi-Iriarte, J.
    Saenz-Antonanzas, A.
    Andermatten, J.
    Elua-Pinin, A.
    Aldaba, E.
    Vara, Y.
    Matheu, A.
    NEURO-ONCOLOGY, 2019, 21 : 53 - 54
  • [17] Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor
    Silva, Jose
    Yu, Jiyang
    Kalinsky, Kevin
    NATURE CANCER, 2023, 4 (06) : 809 - 811
  • [18] Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor
    Jose Silva
    Jiyang Yu
    Kevin Kalinsky
    Nature Cancer, 2023, 4 : 809 - 811
  • [19] HDAC6: A unique HDAC family member as a cancer target
    Sumeet Kaur
    Prerna Rajoria
    Madhu Chopra
    Cellular Oncology, 2022, 45 : 779 - 829
  • [20] HDAC6: A unique HDAC family member as a cancer target
    Kaur, Sumeet
    Rajoria, Prerna
    Chopra, Madhu
    CELLULAR ONCOLOGY, 2022, 45 (05) : 779 - 829